HHATL: A Potential Drug Target for Cancer and Neurodegenerative Diseases

Target Name: HHATL

NCBI ID: G57467

HHATL

HHATL: A Potential Drug Target for Cancer and Neurodegenerative Diseases

Hedgehog acyltransferase like (HHATL) is a gene that encodes a protein located in the endoplasmic reticulum (ER) and known to be involved in the transport of various molecules, including lipids and phospholipids. The HHATL gene has four known splice variants, each with a different exon order and a different amino acid sequence. HHATL has been shown to play a crucial role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and metabolic disorders. As a result, HHATL has emerged as a promising drug target and biomarker for a variety of diseases.

The HHATL gene is located on chromosome 1p36 and encodes a protein with a molecular weight of approximately 56 kDa. The protein is composed of 115 amino acids and has a calculated pI of 9.97. The HHATL protein is expressed in various tissues and cells, including liver , muscle, brain, and placenta, and is involved in the transport of different molecules to their destination.

One of the most significant functions of the HHATL protein is its role in the transport of phospholipids to the endoplasmic reticulum (ER). The ER is a membrane-wrapped organelle, where various enzymes are involved in the synthesis and modification of phospholipids, such as lipoproteins, phosphatidyl choline, and phospholipase A2 (PLA2). The HHATL protein is shown to be involved in the movement of these phospholipids to the ER, where they can be targeted by other enzymes for their various functions.

HHATL has been shown to play a key role in the development and progression of various diseases, including cancer. For example, studies have shown that high levels of HHATL are associated with poor prognosis in patients with pancreatic cancer, a highly aggressive form of cancer that is characterized by the formation of tumors that infiltrate the surrounding tissue and have a high mortality rate. Additionally, HHATL has been shown to be involved in the regulation of cell signaling pathways, including the TGF-β pathway, which plays a crucial role in the development and maintenance of tissues and organs.

HHATL has also been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles, which are thought to be caused by the build -up of abnormal proteins in the brain. Studies have shown that HHATL is involved in the production of these abnormal proteins and may play a role in the development and progression of these conditions.

In addition to its involvement in cancer and neurodegenerative diseases, HHATL has also been shown to be involved in the regulation of various metabolic processes. For example, HHATL has been shown to be involved in the transport of different lipids to the liver, where they can be used for energy production. Additionally, HHATL has been shown to play a role in the regulation of lipid metabolism, including the production of bile and the transport of lipids to the small intestine for absorption.

In conclusion, HHATL is a gene that has been shown to play a crucial role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and metabolic disorders. As a result, HHATL has emerged as a promising drug target and biomarker for a variety of diseases. Further research is needed to fully understand the functions of HHATL and to develop effective therapies for the treatment of these conditions.

Protein Name: Hedgehog Acyltransferase Like

Functions: Negatively regulates N-terminal palmitoylation of SHH by HHAT/SKN

The "HHATL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HHATL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets